Supplementary Figure 8 from GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB

Abstract

PDF file - 1842K, GSK-3 inhibition leads to a decrease in TAK1 levels and p100-p52 processing in a statistically significant manner. All data obtained with independent experiments with Panc-1 and MiaPaCa-2, treated with GSK-3 inhibitor for 24 hours (right panel) or transiently transfected with indicated siRNA's for 72 hours (left panel) were quantified by densitometric analyses and is expressed as mean�SD. Statistical evaluation of the differences were calculated using students two-tailed t test and P value < 0.05 was considered significant.</p